Eleni Andreopoulou
Overview
Explore the profile of Eleni Andreopoulou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koundouros N, Nagiec M, Bullen N, Noch E, Burgos-Barragan G, Li Z, et al.
Science
. 2025 Mar;
387(6739):eadm9805.
PMID: 40080571
Diet influences macronutrient availability to cells, and although mechanisms of sensing dietary glucose and amino acids are well characterized, less is known about sensing lipids. We defined a nutrient signaling...
2.
Nicolo E, Serafini M, Munoz-Arcos L, Pontolillo L, Molteni E, Bayou N, et al.
J Liq Biopsy
. 2025 Mar;
2:100117.
PMID: 40028485
The human epidermal growth factor receptor 2 (HER2) plays a central role in breast cancer (BC). Therefore, it is critical to develop a method that can capture its spatial and...
3.
Ivanidze J, Sharbatdaran A, McCalla A, Brandmaier A, Andreopoulou E, Cristofanilli M, et al.
Eur J Radiol
. 2024 Oct;
181:111791.
PMID: 39423781
Objective: Our purpose was to describe our initial institutional experience using dedicated brain [18F]-Fluoroestradiol (FES) PET/CT or PET/MRI in the management of patients with estrogen-receptor-positive (ER+) breast cancer brain metastases...
4.
Chavez-MacGregor M, Miao J, Pusztai L, Goetz M, Rastogi P, Ganz P, et al.
J Clin Oncol
. 2024 Jun;
42(25):3012-3021.
PMID: 38833643
Purpose: Phosphatidylinositol 3-kinase/AKT-serine threonine kinase/mammalian target of rapamycin (mTOR) pathway abnormalities contribute to endocrine resistance. Everolimus, an mTOR inhibitor, improved progression-free survival in hormone receptor-positive metastatic breast cancer (BC) when...
5.
Nicolo E, Gianni C, Pontolillo L, Serafini M, Munoz-Arcos L, Andreopoulou E, et al.
Transl Breast Cancer Res
. 2024 May;
5:10.
PMID: 38751670
Liquid biopsy has emerged as a crucial tool in managing breast cancer (BC) patients, offering a minimally invasive approach to detect circulating tumor biomarkers. Until recently, the majority of the...
6.
Kalinsky K, Accordino M, Chiuzan C, Mundi P, Sakach E, Sathe C, et al.
J Clin Oncol
. 2023 May;
41(24):4004-4013.
PMID: 37207300
Purpose: Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic...
7.
Schreier A, Zappasodi R, Serganova I, Brown K, Demaria S, Andreopoulou E
Front Oncol
. 2023 Jan;
12:1061789.
PMID: 36703796
Triple negative breast cancer (TNBC) is an aggressive disease that is difficult to treat and portends a poor prognosis in many patients. Recent efforts to implement immune checkpoint inhibitors into...
8.
Fasano G, Bayard S, Chen Y, Varella L, Cigler T, Bensenhaver J, et al.
Breast Cancer Res Treat
. 2022 Jan;
192(1):163-173.
PMID: 35022867
Purpose: National comprehensive cancer network guidelines recommend delivery of adjuvant chemotherapy in node-negative triple-negative breast cancer (TNBC) if the tumor is > 1 cm and consideration of adjuvant chemotherapy for...
9.
Orfanelli T, Giannopoulos S, Zografos E, Athanasiou A, Bongiovanni A, Doulaveris G, et al.
Sci Rep
. 2021 Nov;
11(1):22220.
PMID: 34782665
Peripheral blood mononuclear cells (PBMCs) respond to altered physiological conditions to alleviate the threat. Production of the 70 kDa heat shock protein (HSP70) is up-regulated to protect proteins from degradation....
10.
Foukakis T, Matikas A, Oikonomidou O, Andreopoulou E, Mavroudis D
Breast Care (Basel)
. 2021 Oct;
16(4):422-428.
PMID: 34602950
No abstract available.